Form 4: Cullinan Therapeutics CLO Sells Shares for Tax Obligations

Cullinan Therapeutics' Chief Legal Officer, Jacquelyn L. Sumer, sold 3,742 shares of common stock to cover tax obligations related to vested restricted stock units.

Summary

• Jacquelyn L. Sumer, Chief Legal Officer of Cullinan Therapeutics, Inc. (CGEM), reported a sale of common stock.
• The transaction involved the disposition of 3,742 shares of common stock.
• The shares were sold at a price of $13.62 per share.
• The sale occurred on February 20, 2026.
• The purpose of the sale was to cover personal income tax obligations arising from the vesting of restricted stock units.
• Following this transaction, Ms. Sumer beneficially owns 131,690 shares of Cullinan Therapeutics common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral. The transaction is a routine insider sale for tax purposes, which is a common occurrence and does not reflect a change in the company's operational or financial performance.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Management Comments

• Jacquelyn Sumer sold shares to cover personal income tax obligations upon the vesting of restricted stock units.

Industry Context

StockSavvy.ai notes that sales of shares by executives to cover tax obligations upon the vesting of restricted stock units are a routine and common occurrence in the biotechnology and pharmaceutical industries. These transactions are typically pre-planned and do not usually indicate a change in management's outlook on the company's prospects.

Key Dates

Keywords

Cullinan Therapeutics, CGEM, Insider Trading, Form 4, Stock Sale, Executive Compensation, Restricted Stock Units, Tax Obligations